8-K: Karyopharm Secures Major Refinancing, Extends Debt Maturities to 2028 and 2029

Karyopharm Therapeutics has successfully refinanced a significant portion of its debt, extending maturities to 2028 and 2029, and reducing its obligations to HealthCare Royalty Management.

Summary

• Karyopharm Therapeutics has entered into a series of transactions to refinance its debt and improve its financial position.
• The company secured a new $100 million senior secured term loan facility maturing in 2028.
• A portion of the loan proceeds, $49.5 million, will be used to repay obligations to HealthCare Royalty Management (HCRx).
• Approximately $148 million of existing convertible notes due in 2025 were exchanged for $111 million of new convertible notes due in 2029 and warrants to purchase 46 million shares.
• HCRx agreed to purchase $5 million of the new convertible notes, reducing their debt by $5 million.
• The new term loan bears interest at a variable rate of Term SOFR plus 9.25%, with a 3% floor.
• The new convertible notes have a 6% interest rate and are convertible at an initial price of $2.25 per share.
• The company's royalty rate on selinexor revenue was reduced from a tiered schedule to a flat 7.0%.

Sentiment

Score: 8

Explanation: The refinancing is a positive development for Karyopharm, significantly improving its financial stability and extending its runway. The reduction in the royalty rate is also a major positive. However, the high interest rate on the term loan and the restrictions imposed by the loan agreements are potential concerns.

Positives

• The refinancing extends the company's debt maturities to 2028 and 2029, providing more financial flexibility.
• The reduction in the royalty rate on selinexor revenue to 7.0% will improve future profitability.
• The new term loan provides $100 million in capital for general corporate purposes and clinical trial activities.
• The exchange of convertible notes reduces the company's near-term debt obligations.
• The company has secured strong commitment from HealthCare Royalty and top convertible note holders.

Negatives

• The new term loan has a high interest rate of Term SOFR plus 9.25%, with a 3% floor.
• The company is required to maintain a minimum liquidity of $25 million.
• The company is restricted from exclusively licensing, selling or disposing of U.S. rights to oncology indications of selinexor.
• The new debt is secured by substantially all assets of the company and its material subsidiaries.
• The company is subject to various covenants and restrictions under the new loan and indenture agreements.

Risks

• The company's ability to repay the term loan is dependent on future asset sales and condemnation events.
• The company is subject to prepayment premiums and redemption fees on the term loan.
• The company is subject to various events of default under the loan and indenture agreements.
• The company's ability to meet the financial covenant to maintain liquidity of at least $25 million is critical.
• The company's stock price could be negatively impacted by the issuance of new shares upon conversion of the notes and exercise of warrants.

Future Outlook

The company expects the refinancing to provide financial stability and support its ongoing clinical trial activities, with debt maturities extended beyond planned Phase 3 data readouts in 2025. The company intends to use the remaining proceeds of approximately $30 million from the Secured Term Loan to pay transaction expenses and for general corporate purposes, including to support the company's ongoing and planned clinical trial activities.

Management Comments

• We are extremely pleased to have accomplished several important objectives for Karyopharm and our shareholders with this refinancing.
• We successfully strengthened our balance sheet by extending the maturity of the vast majority of our debt obligations well beyond the planned readouts and potential approvals of our three ongoing Phase 3 programs.
• With the demonstrated strong commitment from HealthCare Royalty and our top convertible note holders, we have enhanced our ability to unlock the potential of selinexor.

Industry Context

This refinancing is a strategic move by Karyopharm to secure its financial position and extend its runway, which is crucial for a biotech company with ongoing clinical trials. The company is focusing on its lead drug, selinexor, and this move provides the financial stability to continue its development and commercialization efforts. The reduction in the royalty rate is also a positive step for the company's future profitability.

Comparison to Industry Standards

• The refinancing strategy is common for biotech companies facing near-term debt maturities, especially those with promising clinical programs.
• The interest rate on the term loan is relatively high, reflecting the risk associated with the company's stage of development and financial position.
• The conversion premium of 105% on the new convertible notes is a standard feature in such transactions, providing an incentive for noteholders to convert to equity.
• The reduction in the royalty rate is a significant benefit for Karyopharm, as it reduces the long-term financial burden associated with its revenue stream.
• Comparable companies in the biotech space often use a combination of debt and equity financing to fund their operations and clinical trials, and this transaction is in line with industry norms.

Related Party Transactions

• HealthCare Royalty Management (HCRx) is a lender under the new term loan and a purchaser of the new convertible notes.
• HCRx is also a party to the amended royalty agreement.

Stakeholder Impact

• Shareholders will benefit from the extended debt maturities and improved financial stability.
• Creditors will have a secured position in the company's assets.
• Employees will benefit from the company's improved financial position and continued operations.
• Customers will benefit from the continued development and commercialization of the company's products.

Next Steps

• The exchange transactions are expected to close on or around May 13, 2024.
• The company will file the Credit Agreement, Exchange Agreement, Indenture, Warrants, Registration Rights Agreement, and Amendment to Agreement with HCRx as exhibits to a Current Report on Form 8-K.
• The company will register for resale the shares of Common Stock underlying the Warrants within 45 days of the New Notes Closing Date.

Key Dates

Keywords

refinancing, debt, convertible notes, term loan, warrants, selinexor, HealthCare Royalty Management, HCRx, maturity, clinical trials